VivoSeq
Infectious Disease

Coccidioidomycosis

5

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Coccidioidomycosis is an early-stage landscape with 5 programs across 6 companies. The most active players are Viatris Specialty LLC, Halcygen Pharmaceuticals Limited, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). 2 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

75/100

Completion Rate

25/100

Attrition Rate

60/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Viatris Specialty LLC

1 program

Phase 2H

Halcygen Pharmaceuticals Limited

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 3S

Sebela Pharmaceuticals Development LLC

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Withdrawn2 · 40%
Completed1 · 20%
Terminated1 · 20%
Recruiting1 · 20%

Clinical Trials

Trial Activity

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00423267·16 enrolled
Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis
Withdrawn·UUniversity of California, San Francisco·Phase 2·NCT02908334
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT02663674·72 enrolled
SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
Withdrawn·—·Phase 2·NCT04809649
The Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02190266·400 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)